#4383 WHEN SHOULD WE TRY TREATMENT FOR PERITONEAL SCLEROSIS?

Abstract Background and Aims Although it is very important to detect patients at increased risk of developing encapsulating peritonitis (EPS), there are not established predictors which would promote early diagnosis treatment EPS ensuring sustainability peritoneal dialysis (PD). D-Dimers considered a significant test in evaluation fibrinolysis activity Ca 125 used as an alternative marker for the integrity membrane.[1] We examined prospectively combination these surrogate markers both serum effluent discern sclerosis. Method In cohort 39 PD D-Dimers, 125, CRP along with complete biochemical profile were tested overnight dialysate beginning study. 9 patients, who presented recurrent gastrointestinal symptoms, such mild nausea, incidence gastric discomfort or sense bloating, CT imaging was performed potent thickening bowel wall measured. The latter group nine received tamoxifene period approximately one year serum/effluent biomarkers repeated end this period. Results Table 1 characteristics shown. At study only biomarker that different between without symptoms (4±6mg/dl vs 0.8±1.1mg/dl, p = 0.04). improved. follow up demonstrated amelioration compared (3±1.2mm 2.1±0.4mm), statistically significant. Moreover, decreased (60.4±74 U/ml 27±27 U/ml, No side effects recorded. Five still on PD, 3 died from unrelated causes transferred hemodialysis. Conclusion neither assessment activity, nor assessing membrane helped us distinguish EPS. fact levels higher treated just before initiation treatment, although some references proposed minimized.[1,2] Clinical radiologic findings led decision treat tamoxifene, exerts protective effect during late stages fibrotic disorders.[3] Despite small number study, showed tendency decrease